Publications
bcSeq: an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens." Bioinformatics 34, no. 20 (2018): 3581-3583.
" BFLCRM: A BAYESIAN FUNCTIONAL LINEAR COX REGRESSION MODEL FOR PREDICTING TIME TO CONVERSION TO ALZHEIMER'S DISEASE." Ann Appl Stat 9, no. 4 (2015): 2153-2178.
" Biclustering via sparse clustering." Biometrics 76, no. 1 (2020): 348-358.
"Biclustering with heterogeneous variance." Proc Natl Acad Sci U S A 110, no. 30 (2013): 12253-8.
"Bidirectional discrimination with application to data visualization." Biometrika 99, no. 4 (2012): 851-864.
"binDesign: Bayesian sample size for non-inferiority randomized trials with binary data (SAS).., 2016.
Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
" Biomarker-based clinical trials., 2012.
Bivariate random effects meta-analysis of diagnostic studies using generalized linear mixed models." Med Decis Making 30, no. 4 (2010): 499-508.
"Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk." Stat Methods Med Res 21, no. 6 (2012): 621-33.
"Block-diagonal discriminant analysis and its bias-corrected rules." Stat Appl Genet Mol Biol 12, no. 3 (2013): 347-59.
" Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis.. Boca Raton: Chapman & Hall / CRC Press, 2016.
Cancer pharmacogenomics: early promise, but concerted effort needed." Science 339, no. 6127 (2013): 1563-6.
" Case-cohort studies with interval-censored failure time data." Biometrika 104, no. 1 (2017): 17-29.
"The case-only independence assumption: associations between genetic polymorphisms and smoking among controls in two population-based studies." Int J Mol Epidemiol Genet 3, no. 4 (2012): 333-60.
"Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial." J Clin Oncol 37, no. 8 (2019): 624-635.
"Censored Rank Independence Screening for High-dimensional Survival Data." Biometrika 101, no. 4 (2014): 799-814.
"Challenges in genome-wide association analysis of drug-induced toxicity data from clinical trials., 2012.
CHANGE POINT ANALYSIS OF HISTONE MODIFICATIONS REVEALS EPIGENETIC BLOCKS LINKING TO PHYSICAL DOMAINS." Ann Appl Stat 10, no. 1 (2016): 506-526.
"Change-Plane Analysis for Subgroup Detection and Sample Size Calculation." J Am Stat Assoc 112, no. 518 (2017): 769-778.
"The Change-Plane Cox Model." Biometrika 105, no. 4 (2018): 891-903.
"Characterizing expected benefits of biomarkers in treatment selection." Biostatistics 16, no. 2 (2015): 383-99.
"Checking semiparametric transformation models with censored data." Biostatistics 13, no. 1 (2012): 18-31.
"Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION)." Am Heart J 165, no. 2 (2013): 193-9.
" Clinical prognostic model for older patients with advanced non-small cell lung cancer." J Geriatr Oncol 10, no. 4 (2019): 555-559.
"Clinical trials data collection: when less is more." J Clin Oncol 28, no. 34 (2010): 5019-21.
" The Closure Principle Revisited., 2014.
CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing." Genome Biol 19, no. 1 (2018): 202.
"CODEX2: Full-spectrum copy number variation detection by high-throughput DNA sequencing. (R)., 2018.
Combining an evolution-guided clustering algorithm and haplotype-based LRT in family association studies." BMC Genet 12 (2011): 48.
"Combining Multiple Observational Data Sources to Estimate Causal Effects." J Am Stat Assoc 115, no. 531 (2020): 1540-1554.
"Comment." J Am Stat Assoc 111, no. 515 (2016): 942-947.
"Comment." J Am Stat Assoc 111, no. 515 (2016): 936-942.
"Comment." Stat Biopharm Res 7, no. 4 (2015): 357-358.
"Comment on "Adaptive Confidence Intervals for the Test Error in Classification"." J Am Stat Assoc 106, no. 495 (2011): 920-924.
"Comment on "Dynamic treatment regimes: technical challenges and applications"." Electron J Stat 8, no. 1 (2014): 1290-1300.
"Common variants in psychiatric risk genes predict brain structure at birth." Cereb Cortex 24, no. 5 (2014): 1230-46.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?" J Biopharm Stat 27, no. 3 (2017): 457-476.
"Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials." Stat Med 36, no. 3 (2017): 403-415.
"A Comparison of Monte Carlo Methods for Computing Marginal Likelihoods of Item Response Theory Models." J Korean Stat Soc 48, no. 4 (2019): 503-512.
"Comparison of operational characteristics for binary tests with clustered data." Stat Med 34, no. 15 (2015): 2325-33.
"A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp." Oncologist 21, no. 7 (2016): 789-94.
"Complete effect-profile assessment in association studies with multiple genetic and multiple environmental factors." Genet Epidemiol 39, no. 2 (2015): 122-33.
"Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates." Bioinformatics 32, no. 1 (2016): 50-7.
"Composite large margin classifiers with latent subclasses for heterogeneous biomedical data." Stat Anal Data Min 9, no. 2 (2016): 75-88.
"A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews." Stat Methods Med Res 26, no. 2 (2017): 914-930.
"Computationally Efficient Estimation for the Generalized Odds Rate Mixture Cure Model with Interval-Censored Data." J Comput Graph Stat 27, no. 1 (2018): 48-58.
"Concordance-Assisted Learning for Estimating Optimal Individualized Treatment Regimes." J R Stat Soc Series B Stat Methodol 79, no. 5 (2017): 1565-1582.
"CONCUR: Kernel-based association test for copy number variation (CNV) aggregate analysis (R)., 2020.
A Confidence Region Approach to Tuning for Variable Selection." J Comput Graph Stat 21, no. 2 (2012): 295-314.
"Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
"Consistency and overfitting of multi-omics methods on experimental data." Brief Bioinform 21, no. 4 (2020): 1277-1284.
"Consistent Group Identification and Variable Selection in Regression with Correlated Predictors." J Comput Graph Stat 22, no. 2 (2013): 319-340.
"Consistent high-dimensional Bayesian variable selection via penalized credible regions." J Am Stat Assoc 107, no. 500 (2012): 1610-1624.
"A Consistent Information Criterion for Support Vector Machines in Diverging Model Spaces." J Mach Learn Res 17, no. 16 (2016): 1-26.
"Continual reassessment method with regularization in phase I clinical trials." J Biopharm Stat 30, no. 6 (2020): 964-978.
"Cook's Distance Measures for Varying Coefficient Models with Functional Responses." Technometrics 57, no. 2 (2015): 268-280.
"A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
" Creating an mHealth App for Colorectal Cancer Screening: User-Centered Design Approach." JMIR Hum Factors 6, no. 2 (2019): e12700.
"CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223.
"CRM2DIM: Dual-Agent Bayesian Continual Reassessment Method (SAS). 1.0 ed., 2019.
cSFM: Covariate-adjusted skewed functional model (R).. 1.1 ed., 2014.
CTD Systems (Java)., 2017.
Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"Data fraud in clinical trials." Clin Investig (Lond) 5, no. 2 (2015): 161-173.
" Deep advantage learning for optimal dynamic treatment regime." Stat Theory Relat Fields 2, no. 1 (2018): 80-88.
" Design of Phase II Non-inferiority Trials." Contemp Clin Trials Commun 7 (2017): 23-27.
"Design of phase III clinical trials." In Oncology Clinical Trials: Successful Design, Conduct, and Analysis. New York: Demos Medical Publishing, LLC, 2010.
" Designing penalty functions in high dimensional problems: The role of tuning parameters." Electron J Stat 10, no. 2 (2016): 2312-2328.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Determining the Number of Latent Factors in Statistical Multi-Relational Learning." J Mach Learn Res 20 (2019).
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
" Diagnostic Measures for the Cox Regression Model with Missing Covariates." Biometrika 102, no. 4 (2015): 907-923.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results." J Biopharm Stat 28, no. 4 (2018): 633-644.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"